This medicine is authorised for use in the European Union.


Telzir is an antiviral medicine for treating patients aged 6 years or above who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).

Telzir is used in combination with ritonavir and other HIV medicines. It contains the active substance fosamprenavir.

This EPAR was last updated on 23/08/2022

Authorisation details

Product details
Agency product number
Active substance
fosamprenavir calcium
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
ViiV Healthcare BV
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Van Asch van Wijckstraat 55H
3811 LP Amersfoort
The Netherlands

Product information

19/08/2022 Telzir - EMEA/H/C/000534 - IG1531

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Telzir in combination with low-dose ritonavir is indicated for the treatment of human-immunodeficiency-virus-type-1-infected adults, adolescents and children of six years and above in combination with other antiretroviral medicinal products.

In moderately antiretroviral-experienced adults, Telzir in combination with low-dose ritonavir has not been shown to be as effective as lopinavir / ritonavir. No comparative studies have been undertaken in children or adolescents.

In heavily pretreated patients, the use of Telzir in combination with low-dose ritonavir has not been sufficiently studied.

In protease-inhibitor-experienced patients, the choice of Telzir should be based on individual viral resistance testing and treatment history.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
1 rating